Applications are invited for a post-doctoral Research Associate to join the Ovarian Cancer Action Research Centre (OCARC) in the Division of Cancer at Imperial (Hammersmith Campus). The OCARC was established with core funding from the charity Ovarian Cancer Action and comprises over 70 researchers from Imperial College Healthcare NHS Trust and Imperial College London. The post holder will take a lead role in newly funded multi-disciplinary programmes of research funded by OCA on ovarian cancer
Epigenetic Therapies (Lead, Professor Bob Brown).
It is our overall objective to provide mechanistic rational, preclinical efficacy data and companion biomarkers of novel epigenetic therapies, particularly to prevent or overcome drug resistance. The successful applicant will use DNA methylation array profiling, ChIPseq and preclinical efficacy studies to evaluate novel epigenetic therapies. Applicants should have experience in wet-lab (gene expression, ChIPseq, drug efficacy studies) and dry lab (bioinformatics, biostatistics) research.